Original InvestigationImpact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy
Under an Elsevier user license
open archive
Central Illustration
Key Words
acetylsalicylic acid
drug-eluting stent
dual antiplatelet therapy
high bleeding risk
P2Y12 inhibitor
Abbreviations and Acronyms
DAPT
dual antiplatelet therapy
IPCW
Inverse probability-of-censoring weights
ITT
intention-to-treat
MACE
major adverse cardiac and cerebral events
MCB
major or clinically relevant nonmajor bleeding
NACE
net adverse clinical events
NARC
nonadherence Academic Research Consortium
OAC
oral anticoagulation
SAPT
single antiplatelet therapy
Cited by (0)
Listen to this manuscript's audio summary by Editor-in-Chief Dr Valentin Fuster on www.jacc.org/journal/jacc.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.
- ∗
A complete list of the MASTER DAPT investigators is provided in the Supplemental Appendix.
© 2022 by the American College of Cardiology Foundation. Published by Elsevier.